肝移植患者中他克莫司血药浓度影响因素-中国药物评价.docVIP

编辑提示：请作者对审改稿件的修订,务必在编辑部提供的以下审稿格式模板上完成,勿另行格式编排,以免增加不必要的重复编排工作量。 谢谢！ 审稿意见： 编辑已对文章标题和摘要进行简单修改，请作者务必再仔细校对修改，出版后文责自负。 请对文中摘要处进行修改。 请尽快修回，以便安排出版。 他克莫司肝移植患者血药浓度影响 650011） [摘要目的：肝移植患者他克莫司（FK506）血药浓度，探讨FK506血药浓度影响因素。方法：筛选我接受肝移植的患者，统计患者的性别、年龄、实际住院天数，以及主要诊断及诊断、FK506的血药浓度及剂量。分析术后时间、用药剂量、性别、年龄等因素与FK506血药浓度的关系。结果：术后14天内与14天后剂量；在同一时间内，性别对的血药浓度有一定的影响；在术后14天内，A组剂量小于B组和C组，血药浓度C组高于A组和B组；在大于14天，C组剂量大于A组和B组，血药浓度C组高于A组和B组。在术后14天内，组剂量14天，组剂量0～5 ug﹒L-1，占总例次的73.17%。结论：他克莫司血药浓度影响因素众多，在使用时应该综合考虑多种因素，以控制血药浓度在理想范围。有利于提高肝移植患者的存活率。 关键词肝移植；他克莫司；血药浓度 Effect Analysis of Blood Concentration of Tacrolimus in Liver Transplantation Patients ZHANG Yang, SONG Cang-sang , LI Xing-de , LU Wei (Department of Pharmacy, the First Peoples Hospital of Kunming City,Yunnan Kunming 650011,China) [Abstaract] Objective: By monitoring the results blood concentration of taking tacrolimus(FK506) in liver transplantation patients to explore the factors affecting the tacrolimus blood concentrations. Methods: Screening the patients undergoing liver transplantation in our hospital from 2010 to 2012, survey the gender, age, the actual number of days in hospital, main diagnosis and other diagnosis and blood drug concentration and dose of FK506. Results: There are significant difference between the group within 14 days and 14 days later of the dose(p＜0.05) and blood drug concentration(p＜0.001) of FK506 in liver transplantation patients. Gender has a certain effect on the blood concentration of FK506 in the same time(p＜0.05). Within 14 days after transplantation, the dose of group A is less than group B and C, blood concentration in group C is higher than group A and group B. In 14 days later after transplantation,the dose and the blood concentration of FK506 in group C are higher than group A and B. Age has a certain effect on the blood concentration of tacrolimus in the same time(p＜0.05), Within 14 days after transplantation, There are no difference at dose of group C compared with group A and B,but the blo